Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.8 USD | +0.42% | +4.09% | -0.77% |
04-12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
04-11 | Barclays Downgrades Exelixis to Equalweight From Overweight, Price Target is $25 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.77% | 6.99B | |
-2.57% | 103B | |
+1.67% | 95.28B | |
+1.46% | 22.15B | |
-15.54% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-12.72% | 16.05B | |
+5.35% | 13.68B | |
+34.43% | 12.17B |
- Stock Market
- Equities
- EXEL Stock
- News Exelixis, Inc.
- Exelixis : Completes Enrollment in Phase 3 Trial of Cabozantinib Combination to Treat Kidney Cancer